Interferon gamma-inducible protein 16 (IFI16) and anti-IFI16 antibodies in primary Sjögren’s syndrome: findings in serum and minor salivary glands

A. Alunno¹, V. Caneparo², F. Carubbi³, O. Bistoni¹, S. Caterbi¹, M. Gariglio², E. Bartoloni¹, S. Landolfo⁴, R. Gerli¹

¹Rheumatology Unit, Department of Medicine, University of Perugia, Perugia; ²Virology Unit, Department of Translational Medicine, Novara Medical School, Novara; ³Rheumatology Unit, Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila; ⁴Viral Pathogenesis Unit, Department of Public Health and Pediatric Sciences, Turin Medical School, Turin, Italy

SUMMARY

The interferon (IFN) signature, namely the overexpression of IFN-inducible genes is a crucial aspect in the pathogenesis of primary Sjögren’s syndrome (pSS). The IFN-inducible IFI16 protein, normally expressed in cell nuclei, may be overexpressed, mislocalized in the cytoplasm and secreted in the extracellular milieu in several autoimmune disorders including pSS. This leads to tolerance breaking to this self-protein and development of anti-IFI16 antibodies. The aim of this study was to identify pathogenic and clinical significance of IFI16 and anti-IFI16 autoantibodies in pSS.

IFI16 and anti-IFI16 were assessed in the serum of 30 pSS patients and one-hundred healthy donors (HD) by ELISA. IFI16 was also evaluated in 5 minor salivary glands (MSGs) of pSS patients and 5 MSGs of non-pSS patients with sicca symptoms by immunohistochemistry.

Normal MSGs do not constitutively express IFI16. Conversely, in pSS-MSGs a marked expression and cytoplasmic mislocalization of IFI16 by epithelial cells was observed with infiltrations in lymphocytes and peri/intra-lesional endothelium. pSS patients display higher serum levels of both IFI16 and anti-IFI16 autoantibodies compared to HD.

Our data suggest that IFI16 protein may be involved in the initiation and perpetuation of glandular inflammation occurring in pSS.

Key words: Sjögren’s syndrome; interferons; IFI16.

INTRODUCTION

Primary Sjögren’s syndrome (pSS) is a chronic autoimmune disorder mainly affecting exocrine glands. The clinical spectrum of pSS ranges from mild symptoms of mucosal dryness to severe extraglandular manifestations. Non-Hodgkin’s lymphoma is the most severe complication (1). The histological hallmark of pSS is a periductal/perivascular mononuclear cell infiltrate of at least 50 lymphocytes (focus). Although the pathogenesis of pSS is not entirely clarified, growing evidence points to the central role of interferon (IFNs) in the initiation and perpetuation of the disease (2, 3). Type I IFNs are early mediators of the innate immune response that foster the adaptive immune response through direct and indirect effects on dendritic cells, T and B cells, and natural killer cells. Increased expression of IFN-inducible genes, namely the type I IFN signature, has been reported in systemic lupus erythematosus, systemic sclerosis (SSc), rheumatoid arthritis and pSS (4-7). Among IFN-inducible genes, the interferon gamma-inducible protein 16 (IFI16), a member of the HIN200/Ifi200 family has been recently investigated in several autoimmune diseases including
IFI16 aberrant overexpression drives early steps of the inflammatory response through nuclear factor kappa B mediated secretion of proinflammatory molecules such as intercellular adhesion molecule 1, E-selectin, interleukin-8 and monocyte chemoattractant protein-1 (12, 14, 15). It is worth noting that an overexpression and mislocalization in the cytoplasm was described in target organs of autoimmune diseases, such as the skin in SSc (16).

IFI16 is also increased in serum samples of patients with autoimmune diseases (8-12). Such events, namely the extracellular spreading of IFI16, lead to the breaking of tolerance to this self-protein and eventually to the development of anti-IFI16 autoantibodies (17).

On this basis, it is reasonable to speculate that IFI16 may act as an autoantigen in pSS and therefore be involved in the development of autoimmunity (14). The aim of this study was to investigate possible pathogenic, diagnostic and prognostic significance of IFI16 protein and anti-IFI16 autoantibodies in patients with pSS.

**MATERIALS AND METHODS**

**Patients**

Thirty consecutive patients with pSS, classified according to the European-American criteria (18), were enrolled. One-hundred sex- and age-matched healthy donors (HD) were selected as controls. Five pSS minor salivary glands (MSGs), collected at the time of diagnosis, were also retrospectively evaluated. Five normal MSGs obtained from subjects with sicca symptoms, but without any clinical and serological features of pSS, were used as controls. The whole study was approved by the local Ethics Committee and written informed consent was obtained in accordance with the declaration of Helsinki.

**Determination of extracellular IFI16 protein by capture ELISA**

A capture ELISA was used to measure the circulating extracellular IFI16 protein with a procedure described below (10).

**Determination of antibody titres towards human recombinant IFI16 by ELISA**

To detect anti-IFI16 antibodies, polystyrene micro-well plates (Nunc-Immuno MaxiSorp; Nunc, Roskilde, Denmark)
were coated with a solution of recombinant IFI16 in phosphate-buffered saline and, after blocking, sera were added in duplicate, as previously described (11, 12).

**Histological analysis of minor salivary glands biopsies**

Labial MSG specimens were scored using hematoxilin-eosin staining sections (focus score, number of foci in 4 mm² of tissue) (19, 20).

IFI16 expression was evaluated using standard immunohistochemistry, as already described in a previous study (17). Images were acquired using an Olympus BX53 fluorescence microscope with CellSens software (Olympus America Inc., Center Valley, PA, USA).

**Statistical analysis**

Data analysis was performed using GraphPad 5.0 software. Mann Whitney U test or Chi square test were used to compare variables among subgroups. The significance level was two sided and set at p<0.05.

### RESULTS

**Serum IFI16 protein and anti-IFI16 antibody are highly expressed in primary Sjögren’s syndrome**

Cut-off values were established according to the 95th percentile of the control population, being 27 ng/mL and 113 U/mL for IFI16 protein and anti-IFI16 autoantibodies, respectively.

As shown in Figure 1A and B, serum levels of both IFI16 protein and anti-IFI16 autoantibodies were higher in pSS than in HD (p<0.01 and p<0.0001, respectively). IFI16 was significantly more prevalent in pSS compared to HD as it was detectable in 6/30 patients (21%) and in 5/100 (5%) (p<0.05). Similarly, a significantly higher prevalence in pSS was confirmed also for anti-IFI16 antibodies that were present in 10/30 pSS patients (33%) and in 5/100 HD (5%) (p<0.001).

Table I summarizes clinical and serological features in pSS patients. We failed to observe any clinical or serological differences according to the positivity/concentration of IFI16 or positivity/titer of antiIFI16 autoantibodies.

**IFI16 protein is highly expressed and mislocalized in the cytoplasm at glandular level in primary Sjögren’s syndrome**

Figure 2A and B display a representative normal and pSS MSG stained with hematoxilin and eosin. The histological analysis of normal MSGs revealed that IFI16 protein was not constitutively expressed by the glandular tissue (Fig. 2C). Conversely, in pSS biopsies IFI16 was highly expressed

| Table I - Clinical and serological features of patient cohort. |
|------------------|------------------|
| Number of patients | 30 |
| Female | 30 (100%) |
| Age (mean ± SEM) | 58±2.3 |
| Age at diagnosis (mean ± SEM) | 49±2.4 |
| Disease duration (mean ± SEM) | 8.8±1 |
| Xerostomia | 28 (93) |
| Xerophtalmia | 28 (93) |
| Salivary swelling | 17 (57) |
| Articular involvement | 18 (60) |
| Purpura | 2 (7) |
| Raynaud’s phenomenon | 3 (10) |
| Visceral involvement | 8 (27) |
| Lymphadenopathy | 2 (7) |
| Lymphoma | 1 (3) |
| Hypocomplementemia | 7 (23) |
| Leukopenia | 14 (47) |
| Hypergammaglobulinemia | 17 (57) |
| Monoclonal component | 3 (10) |
| Autoantibodies |  |
| Neither anti-SSA nor anti-SSB | 4 (13) |
| Anti-SSA only | 9 (30) |
| Both anti-SSA and anti-SSB | 17 (57) |
| Rheumatoid factor | 22 (73) |
| Cryoglobulins | 1 (3) |
| Topical drugs | 23 (77) |
| Hydroxicloroquine | 16 (53) |
| Methotrexate | 6 (20) |

Unless specified, values are displayed as number of patients (percentage). SEM, standard error of the mean.
in the nuclei of both ductal and acinar epithelial cells. It is worth noting that IFI16 is aberrantly expressed in the cytoplasm of ductal epithelial cells (Figure 2D). IFI16 nuclear and cytoplasmic staining was also observed in the inflammatory cells infiltrating the tissue (Fig. 2D). Finally, the constitutive expression of IFI16 in the nuclei of endothelial cells that could be detected in normal MSGs was more pronounced in pSS peri- and intra-lesional endothelium (Fig. 2C-D, inserts).

**DISCUSSION AND CONCLUSIONS**

A large body of evidence supports the pathogenic role of the IFN signature in several autoimmune diseases including pSS (6, 21). However several aspects of this pathway as well as the role of each IFN-inducible molecule are not fully elucidated. Our study demonstrated that the IFN inducible protein IFI16 is aberrantly expressed in sera and target organs of patients with pSS. In addition we confirmed that pSS patients display circulating autoantibodies towards IFI16. Therefore, it is reasonable to postulate that IFI16 protein may be involved in the induction and maintenance of glandular inflammation and, more generally, in triggering the autoimmune response.

Previous studies pointed out that IFI16 is involved in the regulation of cell growth, differentiation, and angiogenesis. In fact, its overexpression leads to decreased cell proliferation with a block in the cell cycle progression at the G1-S phase transition of cancer cell lines, and to an impairment of tube morphogenesis and proliferation of human endothelial cells (22, 23).

Our study demonstrated that the IFN inducible protein IFI16 is aberrantly expressed in sera and target organs of patients with pSS. In addition we confirmed that pSS patients display circulating autoantibodies towards IFI16. Therefore, it is reasonable to postulate that IFI16 protein may be involved in the induction and maintenance of glandular inflammation and, more generally, in triggering the autoimmune response. Previous studies pointed out that IFI16 is involved in the regulation of cell growth, differentiation, and angiogenesis. In fact, its overexpression leads to decreased cell proliferation with a block in the cell cycle progression at the G1-S phase transition of cancer cell lines, and to an impairment of tube morphogenesis and proliferation of human endothelial cells (22, 23). IFI16 is expressed in myeloid precursor cells and such expression remains stable throughout the lymphoid development. In addition, the histological evaluation of a variety of normal tissues revealed that IFI16 expression is highly clustered. As far as epithelial cells are concerned, IFI16 expression was described in skin, gastrointestinal tract, urogenital tract, and glands and ducts of breast tissues (13, 24). This tissue-specific physiological expression of IFI16 may indicate that this molecule is involved in the early phases of inflammation.

In this study we demonstrated that, unlike other epithelial cells, those of normal MSGs do not constitutively express IFI16 protein. Conversely, a marked expression of this molecule by acinar and ductal epithelial cells as well as infiltrating lymphocytes and peri/intra-lesional endothelium could be observed during pSS. Hence, IFI16 expression appears to be induced de novo in the target tissue of this disease. Recently, it has been hypothesized that salivary gland epithelial cells are actively involved in the initiation and perpetuation of pSS (25) and IFN appears to be crucial in this scenario. In fact, IFN binding to toll-like receptors aberrantly expressed by activated salivary gland epithelium leads to an up-regulation and mislocalization in the cytoplasm of nuclear proteins. Besides the well-known Ro52 and Ro60 nuclear proteins, our findings suggest that also IFI16 may undergo this fate in pSS-MSGs. In de-
Interferon gamma-inducible protein 16 (IFI16) and anti-IFI16 antibodies

The abnormal release in the extracellular milieu of nuclear proteins normally hidden to the immune system, including IFI16, leads to tolerance breaking, antigen-specific B-cell activation and, eventually, autoantibody production. IFI16, therefore, may act as an autoantigen in pSS being involved in the disease pathogenesis. In addition the evidence that IFI16 is also overexpressed and mislocalized in the cytoplasm of infiltrating lymphocytes further underscores its possible pathogenic role. Finally, the consistent presence of IFI16 in pSS peri/intra-lesional endothelial cells fits with the recent observation that IFI16 overexpression in endothelial cells in another pebble in the mosaic of inflammation (14, 15). The aforementioned observation, together with the evidence that only a subgroup of pSS patients display consistent levels of circulating IFI16, allow us to speculate that the main pathogenic role of IFI16 is exerted at glandular tissue level. Similarly, since IFI16 may exert its role of autoantigen mainly at tissue level, again only a subgroup of patients display circulating anti-IFI16 autoantibodies.

In conclusion, our study provides some bases to understand the pathogenic role of IFI16 and anti-IFI16 autoantibodies in pSS. Larger and prospective studies are required to identify the potential diagnostic and/or prognostic role of IFI16 protein anti-IFI16 autoantibodies in pSS and eventually provide the rationale for their detection in clinical practice.

Contributions: AA and VC equally contributed to this study.

REFERENCES


